<DOC>
	<DOCNO>NCT01321346</DOCNO>
	<brief_summary>This study patient relapse refractory Acute Lymphoblastic Leukemia ( ALL ) , Acute Myelogenous Leukemia ( AML ) , Hodgkin 's Disease ( HD ) Non-Hodgkin 's Lymphoma ( NHL ) . Panobinostat new drug consider investigational approve United States Food Drug Administration ( FDA ) , country . Panobinostat histone deacetylase inhibitor ( HDACi ) interfere gene expression find cell cause stop growing die . Panobinostat use several hundred adult leukemia , HD , NHL solid tumor . Panobinostat give child . This phase I study . In phase I study , drug test high dose safely give . Drugs give gradually increase dosage unacceptable side effect . The goal Phase I study find dose panobinostat safely give child relapse ALL , AML , HD NHL .</brief_summary>
	<brief_title>A Study Of Panobinostat In Children With Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Patients must ≤ 21 year age time enrollment . Patients must one following : 1 . Patient must relapsed/refractory acute myelogenous leukemia ( AML ) ≥ 5 % blast bone marrow biopsy confirm chloroma . Patient may CNS 1 , 2 3 disease . Isolated CNS relapse eligible . 2 . Patient must relapsed/refractory acute lymphoblastic leukemia ( ALL ) ≥ 5 blast bone marrow biopsy confirm extramedullary disease . Patient may CNS 1 , 2 3 disease . Isolated CNS relapse eligible . 3 . Patient must relapse refractory nonHodgkin 's lymphoma ( NHL ) Hodgkin 's disease . Patients must CNS 1 disease . Patient must histologic verification disease original diagnosis . Patient must measurable disease documented clinical radiographic criterion bone marrow disease present study entry . Karnofsky &gt; 50 % patient &gt; 16 year age Lansky &gt; 50 % patient le equal 16 year age . ( See Appendix I Performance Scales ) . Patient must life expectancy 8 week . PRIOR THERAPY Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . 1 . Patients AML must least 2 prior therapeutic attempt include frontline induction . 2 . Patients ALL must least 3 prior therapeutic attempt include frontline induction . 3 . Radiotherapy : At least 28 day must elapse since radiation therapy . 4 . Hematopoietic Stem Cell Transplant : Patients previous allogeneic HSCT must grade I less GraftversusHost Disease ( GVHD ) receive immunosuppressive medication least 90 day . 5 . Hematopoietic grow factor : It must least 7 day since completion therapy GCSF growth factor time enrollment . It must least 14 day since completion therapy pegfilgrastim ( Neulasta® ) . 6 . Biologic/Immunologic ( antineoplastic ) therapy : It must least 28 day since completion therapy biologic/immunologic agent monoclonal antibody prior study enrollment least 28 day since nonstudy chemotherapy administer , exclude CNS direct therapy describe Section 4.1 . 7 . Prior HSCT Hodgkin 's Lymphoma : Patients Hodgkin 's lymphoma must prior attempt autologous HSCT . Renal Hepatic Function 1 . Patient 's serum creatinine must ≤ 1.5 x institutional upper limit normal ( ULN ) accord age . If serum creatinine great 1.5 time normal , patient must calculate creatinine clearance radioisotope GRF ≥ 70mL/min/1.73m2 . Pediatric Population ( age &lt; 18 ) : Calculated creatinine clearance ≥ 90 ml/min/1.73m2 calculate Schwartz formula estimate glomerular filtration rate ( GFR ) Adult Population ( age &gt; 18 ) : Serum creatinine &lt; 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 2 . Patient 's ALT must &lt; 5 x institutional upper limit norm ULN . 3 . Patient 's total bilirubin must ≤ 1.5 x ULN . Cardiac Function . Patient must shorten fraction ≥ 29 % ejection fraction ≥ 40 % ECHO/MUGA . Reproductive Function 1 . Female patient childbearing potential must negative urine serum pregnancy test confirm prior enrollment . 2 . Female patient infant must agree breastfeed infant study . 3 . Male female patient childbearing potential must agree use effective method contraception approve investigator study . Patients exclude unable swallow capsule whole . Patients exclude receive previous therapy HDAC , DAC , HSP90 inhibitor valproic acid anticancer therapy . Valproic acid therapy allow reason study . AML patient candidate allogeneic stem cell transplant exclude . Patients exclude systemic fungal , bacterial , viral infection exhibit ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment . Gastrointestinal Function 1 . Impairment GI function GI disease may significantly alter absorption panobinostat . 2 . Patients diarrhea &gt; CTCAE grade 2 . Patients exclude plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period , exclude CNS direct therapy upfront AML patient continue CNS positive patient describe Section 4.1 . Cytoreduction hydroxyurea initiate continue 24 hour prior start protocol therapy . Patients exclude significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require . Cardiac Patients exclude meet following : 1 . History presence sustain ventricular tachyarrhythmia . ( Patients history atrial arrhythmia eligible discuss study chair prior enrollment ) . 2 . Any history ventricular fibrillation torsade de pointes . 3 . Bradycardia define HR &lt; 50 bpm . Patients pacemaker eligible HR ≥ 50 bpm . 4 . Screening ECG QTc &gt; 450 msec . 5 . Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug . 6 . Right bundle branch block + leave anterior hemiblock ( bifascicular block ) . 7 . Patients myocardial infarction unstable angina ≤ 6 month prior start study drug . 8 . Other clinically significant heart disease ( e.g. , CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . 9 . Patients leukemia must know refractory red blood cell platelet transfusion .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589</keyword>
	<keyword>Refractory</keyword>
	<keyword>Hodgkin 's</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Acute</keyword>
	<keyword>Childhood</keyword>
	<keyword>Pediatric</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>NHL</keyword>
	<keyword>HD</keyword>
</DOC>